59815-19-9

Usage

Uses

Used in Pharmaceutical Synthesis:
3-(aminosulfonyl)-4-bromobenzoic acid is used as a key intermediate in the pharmaceutical industry for the production of various organic compounds. Its unique combination of functional groups allows for its involvement in a wide range of chemical reactions, facilitating the creation of new drugs and medicinal agents.
Used in Dye Synthesis:
In the dye industry, 3-(aminosulfonyl)-4-bromobenzoic acid is utilized as a precursor in the synthesis of different types of dyes. Its chemical structure contributes to the color properties and stability of the resulting dyes, making it an important component in the formulation of various colorants.
Used in Analytical Chemistry as a Reagent:
3-(aminosulfonyl)-4-bromobenzoic acid serves as a reagent in analytical chemistry for the detection and identification of amines and other organic compounds. Its reactivity with these compounds makes it a valuable tool in qualitative and quantitative analysis, aiding in the accurate determination of the presence and concentration of specific organic substances in various samples.

Upstream product

• 586-76-5 4-Bromobenzoic acid 
• 50803-23-1 4-bromo-3-(chlorosulfonyl)benzoic acid 

Downstream Products

• 35588-54-6 4-bromo-3-sulfamoylbenzoyl chloride 
• 74451-73-3 2-bromo-5-carbomethoxybenzenesulfonamide 
• 1310552-64-7 methyl-4-bromo-3-tetrahydro-1H-2-pyrrolydensulfamoylbenzoate 
• 1310552-65-8 methyl-3-(2-azepanylidensulfamoyl)-4-bromobenzoate 
• 59815-21-3 4'-bromo-3'-sulfamoyl-2-chloroacetophenone 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of 5?substituted sulfonylureas as novel antifungal agents targeting acetohydroxyacid synthase

Acetohydroxyacid synthase (AHAS; EC2.2.1.6) exists solely in plants and microbes, and the biosynthesis of branched chain amino acids (valine, leucine and isoleucine) gets obstructed when sulfonylureas bind to AHAS catalytic subunit active site, which leads to the inability to synthesize these proteins and eventually causes the death of plants and microbes. Thus, the AHAS is also a promising antifungal target. Nowadays, there is an urgent need to discover new potential targets and chemical structures to prevent the growing morbidity and mortality of fungal infections and the emergence of severe antifungal drug resistance. In this work, 36 target compounds were designed and synthesized and several 5-substituted sulfonylureas possess much better antifungal activities than those of Fluconazole (FCZ) and amphotericin B (AMB). The most potent of these were L10, L23 and L31 with inhibition constants (Ki) determined in the range of 5.6～9.6 nM for C. albicans AHAS and MICs(The MIC was determined as the drug concentration that inhibits fungal growth by >90% relative to the corresponding drug-free growth control) a proposed double-pocket binding mode was simulated via molecular docking. The energy gap between the HOMOs and LUMOs of selected compounds showed that the 5-substituted groups of sulfonylureas have key impact on the antimicrobial bioactivity.

Facile synthesis of 4H-1,2,4-benzothiadiazine-1,1-dioxides

o-Bromoarylsulfonylated amidines prepared either by acylation of amidine with o-bromoarylsulfonyl chloride or through the reaction of o-bromoarylsulfoamide with lactime ether underwent Cu(I)-catalyzed intramolecular cyclization to give 4H-1,2,4-benzothiadiazine-1,1-dioxides in good yield. By varying substituents on arylsulfonyl moieties, amidines, and lactime ethers, a small library of structurally diverse 4H-1,2,4- benzothiadiazine-1,1-dioxide derivatives was prepared.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).